Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga Earnings

03/20

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) will release earnings for its fourth quarter before the opening bell on Friday, March 20.

Analysts expect the Montreal, Canada-based company to report a quarterly loss of 16 cents per share on revenue of $1.20 million, according to Benzinga Pro.

On Feb. 10, Milestone Pharmaceuticals named David Sandoval as general counsel and chief compliance officer.

Shares of Milestone Pharmaceuticals closed at $1.70 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

HC Wainwright & Co. analyst Brandon Folkes maintained a Buy rating with a price target of $8 on Jan. 6, 2026. This analyst has an accuracy rate of 46%.
Wells Fargo analyst Mohit Bansal maintained an Overweight rating and increased the price target from $4 to $8 on Dec. 16, 2025. This analyst has an accuracy rate of 68%.
TD Cowen analyst Ritu Baral upgraded the stock from Hold to Buy with a price target of $8 on Dec. 15, 2025. This analyst has an accuracy rate of 49%.

Considering buying MIST stock? Here’s what analysts think:

Photo via Shutterstock

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2620200509"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620200509\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620200509?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 14:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620200509","market":"us","top_or_hot":-1,"title":"Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts","media":"Benzinga Earnings","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/MIST\">Milestone Pharmaceuticals Inc.</a></strong> (NASDAQ:MIST) will release earnings for its fourth quarter before the opening bell on Friday, March 20.</p>\n<p>Analysts expect the Montreal, Canada-based company to report a quarterly loss of 16 cents per share on revenue of $1.20 million, according to Benzinga Pro.</p>\n<p>On Feb. 10, Milestone Pharmaceuticals named David Sandoval as general counsel and chief compliance officer.</p>\n<p>Shares of Milestone Pharmaceuticals closed at $1.70 on Thursday.</p>\n<p>Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>\n<p>Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Brandon Folkes maintained a Buy rating with a price target of $8 on Jan. 6, 2026. This analyst has an accuracy rate of 46%.</li>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Mohit Bansal maintained an Overweight rating and increased the price target from $4 to $8 on Dec. 16, 2025. This analyst has an accuracy rate of 68%.</li>\n<li>TD Cowen analyst Ritu Baral upgraded the stock from Hold to Buy with a price target of $8 on Dec. 15, 2025. This analyst has an accuracy rate of 49%.</li>\n</ul>\n<p>Considering buying MIST stock? Here’s what analysts think: </p>\n<figure><img decoding=\"async\" height=\"519\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445-1024x519.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445-1024x519.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445-768x389.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445.png 1213w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMilestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2026-03-20 14:23</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/MIST\">Milestone Pharmaceuticals Inc.</a></strong> (NASDAQ:MIST) will release earnings for its fourth quarter before the opening bell on Friday, March 20.</p>\n<p>Analysts expect the Montreal, Canada-based company to report a quarterly loss of 16 cents per share on revenue of $1.20 million, according to Benzinga Pro.</p>\n<p>On Feb. 10, Milestone Pharmaceuticals named David Sandoval as general counsel and chief compliance officer.</p>\n<p>Shares of Milestone Pharmaceuticals closed at $1.70 on Thursday.</p>\n<p>Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>\n<p>Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Brandon Folkes maintained a Buy rating with a price target of $8 on Jan. 6, 2026. This analyst has an accuracy rate of 46%.</li>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Mohit Bansal maintained an Overweight rating and increased the price target from $4 to $8 on Dec. 16, 2025. This analyst has an accuracy rate of 68%.</li>\n<li>TD Cowen analyst Ritu Baral upgraded the stock from Hold to Buy with a price target of $8 on Dec. 15, 2025. This analyst has an accuracy rate of 49%.</li>\n</ul>\n<p>Considering buying MIST stock? Here’s what analysts think: </p>\n<figure><img decoding=\"async\" height=\"519\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445-1024x519.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445-1024x519.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445-768x389.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20022128/image-445.png 1213w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51372442/milestone-pharmaceuticals-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts","article_id":"2620200509","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620200509","pubTimestamp":1773987785,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Earnings report for Milestone Pharmaceuticals Inc. (MIST) expected on March 19. Analysts predict 16 cents per share on $1.20M revenue.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","MIST":"Milestone Pharmaceuticals Inc."},"translate_title":"Milestone Pharmaceuticals准备第四季度印刷；以下是华尔街最准确的分析师最近的预测变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIST":1},"content_text":"Milestone Pharmaceuticals Inc. (NASDAQ:MIST) will release earnings for its fourth quarter before the opening bell on Friday, March 20.\nAnalysts expect the Montreal, Canada-based company to report a quarterly loss of 16 cents per share on revenue of $1.20 million, according to Benzinga Pro.\nOn Feb. 10, Milestone Pharmaceuticals named David Sandoval as general counsel and chief compliance officer.\nShares of Milestone Pharmaceuticals closed at $1.70 on Thursday.\nBenzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.\nLet's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.\n\nHC Wainwright & Co. analyst Brandon Folkes maintained a Buy rating with a price target of $8 on Jan. 6, 2026. This analyst has an accuracy rate of 46%.\nWells Fargo analyst Mohit Bansal maintained an Overweight rating and increased the price target from $4 to $8 on Dec. 16, 2025. This analyst has an accuracy rate of 68%.\nTD Cowen analyst Ritu Baral upgraded the stock from Hold to Buy with a price target of $8 on Dec. 15, 2025. This analyst has an accuracy rate of 49%.\n\nConsidering buying MIST stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}